<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Eur Urol</journal-id>
        <journal-id journal-id-type="iso-abbrev">Eur. Urol.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>European urology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0302-2838</issn>
        <issn pub-type="epub">1873-7560</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC6007852</article-id>
        <article-id pub-id-type="pmcid-ver">PMC6007852.1</article-id>
        <article-id pub-id-type="pmcaid">6007852</article-id>
        <article-id pub-id-type="pmcaiid">6007852</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS968728</article-id>
        <article-id pub-id-type="pmid">28583311</article-id>
        <article-id pub-id-type="doi">10.1016/j.eururo.2017.05.032</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS968728</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA968728</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pietzak</surname>
              <given-names initials="EJ">Eugene J.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bagrodia</surname>
              <given-names initials="A">Aditya</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cha</surname>
              <given-names initials="EK">Eugene K.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Drill</surname>
              <given-names initials="EN">Esther N.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">b</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="G">Gopa</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Isharwal</surname>
              <given-names initials="S">Sumit</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ostrovnaya</surname>
              <given-names initials="I">Irina</given-names>
            </name>
            <xref ref-type="aff" rid="A2">b</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Baez</surname>
              <given-names initials="P">Priscilla</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names initials="Q">Qiang</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zehir</surname>
              <given-names initials="A">Ahmet</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosenberg</surname>
              <given-names initials="JE">Jonathan E.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bajorin</surname>
              <given-names initials="DF">Dean F.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dalbagni</surname>
              <given-names initials="G">Guido</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Al-Ahmadie</surname>
              <given-names initials="H">Hikmat</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bochner</surname>
              <given-names initials="BH">Bernard H.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref ref-type="author-notes" rid="FN1">*</xref>
          </contrib>
        </contrib-group>
        <aff id="A1">
<label>a</label>Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A2">
<label>b</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A3">
<label>c</label>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A4">
<label>d</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A5">
<label>e</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <author-notes>
          <corresp id="FN1"><label>*</label>Corresponding author. Urology Service, Department of Surgery, Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA. Tel. +1 646 422 4387; Fax: +1 212 988 0759</corresp>
          <fn fn-type="COI-statement" id="FN4">
            <p id="P44"><bold><italic toggle="yes">Financial disclosures:</italic></bold> Bernard H. Bochner certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>03</day>
          <month>6</month>
          <year>2017</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>12</month>
          <year>2017</year>
        </pub-date>
        <volume>72</volume>
        <issue>6</issue>
        <issue-id pub-id-type="pmc-issue-id">315458</issue-id>
        <fpage>952</fpage>
        <lpage>959</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>07</day>
              <month>06</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>12</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>12</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-11-08 10:25:38.940">
              <day>08</day>
              <month>11</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms968728.pdf"/>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="editorial" journal-id="Transl Androl Urol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC5760389">
          <article-title>Next-generation sequencing in non-muscle-invasive bladder cancer—a step towards personalized medicine for a superficial bladder tumor</article-title>
          <volume>6</volume>
          <issue>6</issue>
          <date>
            <month>12</month>
            <year>2017</year>
          </date>
          <fpage>1198</fpage>
          <lpage>1202</lpage>
          <source>Translational Andrology and Urology</source>
          <pub-id pub-id-type="pmcid">PMC5760389</pub-id>
          <pub-id pub-id-type="pmid">29354512</pub-id>
        </related-article>
        <abstract>
          <sec id="S1">
            <title>Background</title>
            <p id="P1">Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel therapeutic strategies.</p>
          </sec>
          <sec id="S2">
            <title>Objective</title>
            <p id="P2">To identify genetic alterations with potential clinical implications in NMIBC.</p>
          </sec>
          <sec id="S3">
            <title>Design, setting, and participants</title>
            <p id="P3">Pretreatment index tumors and matched germline DNA from 105 patients with NMIBC on a prospective Institutional Review Board-approved protocol underwent targeted exon sequencing analysis in a Clinical Laboratory Improvement Amendments-certified clinical laboratory.</p>
          </sec>
          <sec id="S4">
            <title>Outcome measurements and statistical analysis</title>
            <p id="P4">Comutation patterns and copy number alterations were compared across stage and grade. Associations between genomic alterations and recurrence after intravesical bacillus Calmette-Guérin (BCG) were estimated using Kaplan-Meier and Cox regression analyses.</p>
          </sec>
          <sec id="S5">
            <title>Results and limitations</title>
            <p id="P5"><italic toggle="yes">TERT</italic> promoter mutations (73%) and chromatin-modifying gene alterations (69%) were highly prevalent across grade and stage, suggesting these events occur early in tumorigenesis. <italic toggle="yes">ERBB2</italic> or <italic toggle="yes">FGFR3</italic> alterations were present in 57% of high-grade NMIBC tumors in a mutually exclusive pattern. DNA damage repair (DDR) gene alterations were seen in 30% (25/82) of high-grade NMIBC tumors, a rate similar to MIBC, and were associated with a higher mutational burden compared with tumors with intact DDR genes (<italic toggle="yes">p</italic> &lt; 0.001). <italic toggle="yes">ARID1A</italic> mutations were associated with an increased risk of recurrence after BCG (hazard ratio = 3.14, 95% confidence interval: 1.51–6.51, <italic toggle="yes">p</italic> = 0.002).</p>
          </sec>
          <sec id="S6">
            <title>Conclusions</title>
            <p id="P6">Next-generation sequencing of treatment-naive index NMIBC tumors demonstrated that the majority of NMIBC tumors had at least one potentially actionable alteration that could serve as a target in rationally designed trials of intravesical or systemic therapy. DDR gene alterations were frequent in high-grade NMIBC and were associated with increased mutational load, which may have therapeutic implications for BCG immunotherapy and ongoing trials of systemic checkpoint inhibitors. <italic toggle="yes">ARID1A</italic> mutations were associated with an increased risk of recurrence after BCG therapy. Whether <italic toggle="yes">ARID1A</italic> mutations represent a predictive biomarker of BCG response or are prognostic in NMIBC patients warrants further investigation.</p>
          </sec>
          <sec id="S7">
            <title>Patient summary</title>
            <p id="P7">Analysis of frequently mutated genes in <italic toggle="yes">superficial</italic> bladder cancer suggests potential targets for personalized treatment and predictors of treatment response, and also may help develop noninvasive tumor detection tests.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>AT-Rich interaction domain 1A</kwd>
          <kwd>Bacillus Calmette-Guérin</kwd>
          <kwd>DNA damage repair</kwd>
          <kwd>Genomics</kwd>
          <kwd>Immunotherapy</kwd>
          <kwd>Nonmuscle invasive bladder cancer</kwd>
          <kwd>Targeted therapy</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
